CAPR250117C20000
- 0.08
- -0.02-20.00%
Capricor Therapeutics Newsroom
Maxim Group Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $25
Maxim Group Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $25
Capricor Therapeutics: Promising Advances in Duchenne Cardiomyopathy Treatment Drive Buy Rating
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $77
Capricor Therapeutics Analyst Ratings
JonesTrading Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $40
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $43
Piper Sandler Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $35
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $43
Capricor Therapeutics Analyst Ratings
Capricor Therapeutics Initiated With a Buy at JonesResearch
Maxim Group Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $25
Cantor Fitzgerald Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Raises Target Price to $30
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $43
Piper Sandler Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $35
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $77
Capricor Therapeutics: Strategic Positioning and Financial Stability Drive Buy Rating
Capricor Therapeutics Analyst Ratings
Piper Sandler Initiates Capricor Therapeutics(CAPR.US) With Buy Rating, Announces Target Price $35
Capricor Therapeutics Initiated With an Overweight at Piper Sandler